Page last updated: 2024-11-02

pamidronate and Pain

pamidronate has been researched along with Pain in 138 studies

Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Research Excerpts

ExcerptRelevanceReference
"To assess outcomes of young patients with osteonecrosis (ON) treated with pamidronate in terms of relief of pain, prevention of progress and bony collapse of involved area."9.12Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes. ( Nguyen, T; Zacharin, MR, 2006)
"This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate."9.12Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. ( Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G, 2006)
"Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis."9.11[Pamidronate in treatment of pain caused by bone metastasis]. ( Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004)
"5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate."9.11Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. ( Allington, N; Gerard, P; Vivegnis, D, 2005)
"To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis."9.11[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005)
"Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function."9.10Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002)
" To evaluate the therapeutic effects of Disodium Pamidronate (Bonin) on bone pain in multiple myeloma."9.10[Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma]. ( Chen, SL; Leng, Y; Shi, HZ, 2002)
" There were no sustained significant differences between the pamidronate and placebo groups in self-reported pain measurements, analgesic use, proportion of patients with an SRE, or mobility at week 9 or 27."9.10Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. ( Kowalski, MO; Petrone, S; Seaman, JJ; Small, EJ; Smith, MR, 2003)
"13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy."9.10Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002)
"The aim of this double-blind, randomized study was to compare the effects of two pamidronate dosages, given as repeated infusions in patients with advanced malignant osteolytic bone disease and bone pain."9.09Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. ( Bacchus, L; Koeberle, D; Senn, HJ; Thuerlimann, B, 1999)
"Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy."9.08Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996)
" 40 patients with progressing painful bone metastases received 45 mg pamidronate by 1-h infusion every 3 weeks."9.08Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. ( Alessandroni, P; Casadei, V; Cascinu, S; Catalano, G; Del Ferro, E, 1996)
"Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy."9.08Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998)
"In an uncontrolled observational study involving 30 children who were 3 to 16 years old and had severe osteogenesis imperfecta, we administered pamidronate intravenously (mean [+/-SD] dose, 6."9.08Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. ( Bishop, NJ; Chabot, G; Glorieux, FH; Lanoue, G; Plotkin, H; Travers, R, 1998)
"47 patients with progressive, painful, predominantly lytic bone metastases from breast cancer were included in a randomised double-blind phase II trial comparing the effects of pamidronate 150 and 300 mg daily."9.08A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. ( Coleman, RE; Ford, J; Houston, S; Kandra, A; Purohit, OP; Rubens, RD, 1998)
" Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose-ranging trial."9.07Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. ( Browning, S; Fram, RJ; George, S; Glover, D; Keller, A; Lipton, A; Macerata, RS; Miller, AA; Seaman, JJ; Zelenakas, K, 1994)
"Selective aspects of quality of life during supportive pamidronate (APD) treatment were assessed in breast cancer patients with osteolytic metastases."9.07The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. ( Aaronson, NK; Bijvoet, OL; Cleton, FJ; Hermans, J; van Dam, FS; van den Bos, B; van Emmerik, B; van Holten-Verzantvoort, AT; Zwinderman, AH, 1991)
"To explore the effects of pamidronate disodium combined with calcium on BMD values and the severity of pain in elderly patients with osteoporosis based on the mobile terminal platform for the Internet of Things."8.12Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things. ( Bai, Z; Guo, P; Kang, M; Wang, D; Wang, J, 2022)
"To investigate if intravenous pamidronate improves bone density in a cohort of patients with chronic neurological conditions and low bone density, in whom fractures and bone pain are impacting on care."7.76Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. ( Davis, E; Howe, W; Valentine, J, 2010)
"To evaluate the effect of intravenous pamidronate therapy on everyday activities, well-being, skeletal pain and bone density in children with osteogenesis imperfecta (OI)."7.74Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. ( Aström, E; Eliasson, AC; Löwing, K; Oscarsson, KA; Söderhäll, S, 2007)
"To evaluate reported cases of scleritis and other ocular side effects associated with pamidronate disodium, with emphasis on previously unreported cases of scleritis."7.72Scleritis and other ocular side effects associated with pamidronate disodium. ( Fraunfelder, FT; Fraunfelder, FW; Jensvold, B, 2003)
" We studied patterns of pagetic pain in relation to physical activity, and the effect of coexistent osteoarthritis (OA)/pagetic arthropathy on pain and physical activity before and after treatment with pamidronate."7.72Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate. ( Mehan, R; Miller, H; Swinson, DR; Talwalkar, A; Vasireddy, S, 2003)
"To report the clinical experience with pamidronate in childhood SAPHO syndrome."7.72Pamidronate in the treatment of childhood SAPHO syndrome. ( Beresford, MW; Cleary, AG; Davidson, JE; Kerrison, C, 2004)
"A 62-yr-old woman with thyroid carcinoma metastatic to bone, and a history of subclinical hypoparathyroidism was admitted to the hospital in hypocalcemic crisis 5 wk after receiving iv pamidronate."7.71Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. ( Jonklaas, J; Mishra, A; Wong, L, 2001)
"Pamidronate treatment improves bone quality in children with mild types of OI."6.71Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. ( Kanumakala, S; Zacharin, M, 2004)
"Pamidronate was well tolerated in the majority of the patients both during the first six infusions and during the whole study period."6.70The role of disodium pamidronate in the management of bone pain due to malignancy. ( Boffi, R; Brunelli, C; Cazzaniga, M; De Conno, F; Groff, L; Panzeri, C; Ripamonti, C; Zecca, E, 2001)
"Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia."6.69Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998)
"Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status."6.41[Pamidronate in the treatment of bone metastases from breast cancer]. ( Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002)
" Oral etidronate given daily showed no clinical benefit, whereas the use of oral clodronate daily did reduce the development of new osteolytic lesions but did not significantly affect bone pain or rates of pathologic fractures."6.18Bisphosphonates in multiple myeloma. ( Berenson, JR, 1997)
"Treatment with pamidronate is beneficial for the patient, family and society, increases mobility and bone density, improves quality of life and reduces family dependence in children with OI."5.46Therapy with pamidronate in children with osteogenesis imperfecta. ( Brad, GF; Mang, N; Marginean, O; Mozos, I; Tamasanu, RC, 2017)
"Zoledronic acid also attenuated mechanical hyperalgesia associated with chronic peripheral neuropathy and inflammation in the rat."5.31Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. ( Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K, 2002)
"Treatment with pamidronate, an inhibitor of osteoclastic bone resorption, given every 2 weeks by i."5.31Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. ( Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimasu, T; Yoshimura, G, 2001)
"Our study confirmed that pamidronate, prednisone, and guideline-recommended anticonvulsants were effective for reducing pain intensity for CPSP."5.22Pharmacotherapies for Central Post-Stroke Pain: A Systematic Review and Network Meta-Analysis. ( Bo, Z; Gangfeng, G; Jian, W; Jian, Y; Ke, H; Maoxia, L; Xiaojing, L; Xiaolan, L; Yan, L; Yang, F; Zhao, C, 2022)
"Bisphosphonate use, in particular pamidronate, improved pain scores, analgesic requirement and musculoskeletal function in patients with osteonecrosis occurring as a complication of childhood ALL therapy."5.14Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL). ( Carter, T; Cole, C; Kotecha, RS; Lee, SJ; Murray, KJ; Powers, N, 2010)
"Patients with either progressive bone metastases or SREs while on clodronate or pamidronate may experience significant pain palliation with a switch to a more potent bisphosphonate."5.13A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy. ( Clemons, M; Cole, DE; Dranitsaris, G; Ooi, W, 2008)
"Our aim was to compare the analgesic efficacy of pamidronate (PAM) and synthetic human calcitonin (CT) in intravenous infusion for recent painful benign vertebral compression in a randomised prospective double-blind study."5.12Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study. ( Cantagrel, A; Cantogrel, S; Constantin, A; Jamard, B; Laroche, M; Mazières, B; Zabraniecki, L, 2006)
"To assess outcomes of young patients with osteonecrosis (ON) treated with pamidronate in terms of relief of pain, prevention of progress and bony collapse of involved area."5.12Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes. ( Nguyen, T; Zacharin, MR, 2006)
"It was established that in the course of pamidronate infusion therapy BE levels remained constant, whereas the values in serum alkaline phosphatase and pain intensity scores were significantly reduced."5.12The analgesic effect of pamidronate is not caused by the elevation of beta endorphin level in Paget's disease--a controlled pilot study. ( Barna, I; Bender, T; Donáth, J; Gergely, P; Poór, G, 2006)
"This study evaluated whether additional palliative benefits could be derived from the second-line use of the more potent bisphosphonate zoledronic acid in metastatic breast cancer patients with either progressive bone metastases or skeletal-related events (SRE), despite first-line therapy with either pamidronate or clodronate."5.12Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. ( Clemons, MJ; Cole, DE; Dranitsaris, G; Ooi, WS; Pritchard, KI; Sukovic, T; Trudeau, M; Verma, S; Wong, BY; Yogendran, G, 2006)
"Data concerning the suspension of new skeletal complications, as well as the apparent improvement of overall survival, pain score and ECOG status, suggest that the pamidronate-treatment should not be stopped once started."5.11Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer. ( Balafouta, M; Gennatas, C; Kokakis, J; Kouloulias, VE; Kouvaris, JR; Mystakidou, K; Pistevou-Gombaki, K; Varela, MN; Vlahos, LJ, 2004)
"Clinical studies showed that pamidronate has curative effects on pain induced by bone metastasis."5.11[Pamidronate in treatment of pain caused by bone metastasis]. ( Cai, Y; Chen, YL; Liu, HQ; Liu, MZ; Ren, J; Wang, DJ; Zhan, QY, 2004)
"5) nonambulatory children with cerebral palsy or a neuromuscular disorder received cyclic intravenous administration of pamidronate."5.11Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study. ( Allington, N; Gerard, P; Vivegnis, D, 2005)
"To evaluate the clinical therapeutic value of (188)Re-HEDP combined with pamidronate in breast cancer with bone metastasis."5.11[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis]. ( Chen, SX; DU, JQ; Jiang, NY; Liang, JG; Liu, XG; Lu, XP, 2005)
"Thirteen patients with McCune-Albright syndrome (MAS) and bone fibrous dysplasia (BFD) have been treated for 2-6 years with pamidronate, an aminobisphosphonate which inhibits osteoclastic function."5.10Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome. ( Altare, F; Andreo, M; de Sanctis, C; Lala, R; Masi, G; Matarazzo, P, 2002)
" To evaluate the therapeutic effects of Disodium Pamidronate (Bonin) on bone pain in multiple myeloma."5.10[Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma]. ( Chen, SL; Leng, Y; Shi, HZ, 2002)
" There were no sustained significant differences between the pamidronate and placebo groups in self-reported pain measurements, analgesic use, proportion of patients with an SRE, or mobility at week 9 or 27."5.10Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. ( Kowalski, MO; Petrone, S; Seaman, JJ; Small, EJ; Smith, MR, 2003)
"Pamidronate at 60 mg was compared with pamidronate at 10 mg rather than placebo in view of the high incidence of transient arthralgias upon first IV exposure to the drug."5.10A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. ( Aaron, SL; Chiu, P; Davis, P; Fitzgerald, AA; Homik, J; Jhangri, GS; LeClercq, S; Maksymowych, WP; Russell, AS; Sholter, D; Skeith, KJ; Yan, A, 2002)
"13 patients with treatment-resistant multiple myeloma with advanced osteolytic lesions received combined pamidronate and thalidomide therapy."5.10Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma. ( Baran, W; Ciepłuch, H; Hellmann, A, 2002)
"The aim of this double-blind, randomized study was to compare the effects of two pamidronate dosages, given as repeated infusions in patients with advanced malignant osteolytic bone disease and bone pain."5.09Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial. ( Bacchus, L; Koeberle, D; Senn, HJ; Thuerlimann, B, 1999)
"Patients with stage III multiple myeloma and at least one lytic lesion received either placebo or pamidronate (90 mg) as a four-hour intravenous infusion given every four weeks for nine cycles in addition to antimyeloma therapy."5.08Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. ( Ballester, O; Bell, R; Berenson, JR; Blacklock, HA; Bordoni, R; Dimopoulos, MA; George, S; Heffernan, M; Keller, A; Knight, RD; Kovacs, MJ; Lichtenstein, A; Lipton, A; Porter, L; Reitsma, DJ; Seaman, J; Simeone, J, 1996)
" 40 patients with progressing painful bone metastases received 45 mg pamidronate by 1-h infusion every 3 weeks."5.08Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy. ( Alessandroni, P; Casadei, V; Cascinu, S; Catalano, G; Del Ferro, E, 1996)
" Anderson, the use of the recently approved bisphosphonate pamidronate (Aredia) became a part of the standard of care pathway for the treatment of osteolytic metastases from breast cancer."5.08Fitting new modalities into practice guidelines. ( Theriault, RL, 1997)
"Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy."5.08Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998)
"In an uncontrolled observational study involving 30 children who were 3 to 16 years old and had severe osteogenesis imperfecta, we administered pamidronate intravenously (mean [+/-SD] dose, 6."5.08Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. ( Bishop, NJ; Chabot, G; Glorieux, FH; Lanoue, G; Plotkin, H; Travers, R, 1998)
"47 patients with progressive, painful, predominantly lytic bone metastases from breast cancer were included in a randomised double-blind phase II trial comparing the effects of pamidronate 150 and 300 mg daily."5.08A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer. ( Coleman, RE; Ford, J; Houston, S; Kandra, A; Purohit, OP; Rubens, RD, 1998)
" Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose-ranging trial."5.07Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. ( Browning, S; Fram, RJ; George, S; Glover, D; Keller, A; Lipton, A; Macerata, RS; Miller, AA; Seaman, JJ; Zelenakas, K, 1994)
"Selective aspects of quality of life during supportive pamidronate (APD) treatment were assessed in breast cancer patients with osteolytic metastases."5.07The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer. ( Aaronson, NK; Bijvoet, OL; Cleton, FJ; Hermans, J; van Dam, FS; van den Bos, B; van Emmerik, B; van Holten-Verzantvoort, AT; Zwinderman, AH, 1991)
"Pamidronate, along with other bisphosphonates, has been used for treatment of bone pain secondary to malignant involvement or metastatic disease for years."4.85Pamidronate treatment in rheumatology practice: a comprehensive review. ( Boulman, N; Feld, J; Odeh, M; Rimar, D; Rosner, I; Rozenbaum, M; Slobodin, G, 2009)
" They now constitute the standard treatment for cancer hypercalcemia, for which we recommend a dose of 1,500 mg of clodronate or 90 mg of pamidronate; the latter compound is more potent and has a longer lasting effect."4.80Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. ( Bartl, R; Body, JJ; Burckhardt, P; Delmas, PD; Diel, IJ; Fleisch, H; Kanis, JA; Kyle, RA; Mundy, GR; Paterson, AH; Rubens, RD, 1998)
" In multiple myeloma, one study with oral clodronate has reported a decrease in bone events and two other studies, one with intravenous pamidronate and the other with oral clodronate have both reported a decrease in skeletal events and bone pain."4.80[Bisphosphonates and bone metastases]. ( Berthaud, P; Jadaud, E; Lortholary, A, 1999)
" As regards pamidronate, several open, controlled studies have shown a significant effect on bone pain in 30-70% of breast cancer patients."4.79Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article. ( Strang, P, 1996)
"To explore the effects of pamidronate disodium combined with calcium on BMD values and the severity of pain in elderly patients with osteoporosis based on the mobile terminal platform for the Internet of Things."4.12Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things. ( Bai, Z; Guo, P; Kang, M; Wang, D; Wang, J, 2022)
" Bone cancer was induced by intra-tibial injections of murine mammary carcinoma cells (4T1) in immunocompetent BALB/c mice and treated intraperitoneally for up to 5 weeks with vehicle, rapamycin or pamidronate (a bisphosphonate currently used to reduce bone loss in bone cancer patients)."3.80Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin. ( Abdelaziz, DM; Komarova, SV; Stone, LS, 2014)
"To investigate if intravenous pamidronate improves bone density in a cohort of patients with chronic neurological conditions and low bone density, in whom fractures and bone pain are impacting on care."3.76Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions. ( Davis, E; Howe, W; Valentine, J, 2010)
"To evaluate the effect of intravenous pamidronate therapy on everyday activities, well-being, skeletal pain and bone density in children with osteogenesis imperfecta (OI)."3.74Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta. ( Aström, E; Eliasson, AC; Löwing, K; Oscarsson, KA; Söderhäll, S, 2007)
"To evaluate reported cases of scleritis and other ocular side effects associated with pamidronate disodium, with emphasis on previously unreported cases of scleritis."3.72Scleritis and other ocular side effects associated with pamidronate disodium. ( Fraunfelder, FT; Fraunfelder, FW; Jensvold, B, 2003)
"Intravenous infusions with the bisphosphonate compound pamidronate decrease bone pain and reportedly can lead to refilling of dysplastic lesions in adults with fibrous dysplasia (FD) of bone."3.72Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. ( Glorieux, FH; Munns, C; Plotkin, H; Rauch, F; Travers, R; Zeitlin, L, 2003)
" We studied patterns of pagetic pain in relation to physical activity, and the effect of coexistent osteoarthritis (OA)/pagetic arthropathy on pain and physical activity before and after treatment with pamidronate."3.72Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate. ( Mehan, R; Miller, H; Swinson, DR; Talwalkar, A; Vasireddy, S, 2003)
"To report the clinical experience with pamidronate in childhood SAPHO syndrome."3.72Pamidronate in the treatment of childhood SAPHO syndrome. ( Beresford, MW; Cleary, AG; Davidson, JE; Kerrison, C, 2004)
" Intravenous pamidronate treatment given monthly for a year was well tolerated and produced dramatic clinical effects, with reduction in bone pain and improvements in mobility, despite incomplete suppression of bone resorption as assessed by biochemical, radiographic and histological criteria."3.71The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment. ( Baker, N; Cundy, T; David, G; Hofman, P; King, A; Noble, J; Robinson, C; Sillence, D, 2002)
") (brittle bone disease) is primarily supportive; early introduction of cyclic intravenous pamidronate administration in children younger than 2 years of age is an innovative and promising therapeutic approach."3.71[Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report]. ( al-Jazayri, Z; Amiour, M; Desrosieres, H; Eckart, P; Guillot, M, 2001)
"A 62-yr-old woman with thyroid carcinoma metastatic to bone, and a history of subclinical hypoparathyroidism was admitted to the hospital in hypocalcemic crisis 5 wk after receiving iv pamidronate."3.71Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism. ( Jonklaas, J; Mishra, A; Wong, L, 2001)
"Three children (ages 9 to 11 years) with osteoporosis pseudoglioma syndrome who had multiple vertebral collapse were treated over a 2-year period with intermittent intravenous bisphosphonate infusions (pamidronate in 2, clodronate in 1)."3.70Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates. ( Cundy, T; Zacharin, M, 2000)
" One of the earliest agents to be investigated, etidronate, is effective in the management of malignant hypercalcemia and, when used orally and intermittently, results in reduced bone loss in osteoporosis."3.69Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. ( Ashley, S; Hanson, J; Kanis, JA; McCloskey, E; Paterson, AH; Powles, TJ, 1995)
" We performed a clinical study to evaluate the therapeutic effect of Disodium Pamidronate over pain and radiologic evolution in bone metastases (Breast Cancer and Multiple Myeloma patients)."3.68[Disodium pamidronate (APD) in the treatment of bone metastases]. ( Costa, L; da Costa, EB; Moreira, C, 1993)
"One of the main features of McCune-Albright syndrome is bone fibrous dysplasia (BFD) often associated with severe clinical outcomes, such as bone pain, bone deformities and pathological fractures."2.72Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome. ( Andreo, M; Bellone, J; Corrias, A; de Sanctis, C; Lala, R; Marzari, D; Matarazzo, P, 2006)
"Pamidronate treatment improves bone quality in children with mild types of OI."2.71Pamidronate treatment of less severe forms of osteogenesis imperfecta in children. ( Kanumakala, S; Zacharin, M, 2004)
"Skeletal metastases from thyroid cancer are poorly responsive to medical or radioiodine treatment."2.70Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. ( Abbruzzese, A; Caraglia, M; Ciccarelli, A; Fonderico, F; Lupoli, G; Martignetti, A; Nuzzo, V; Vitale, G, 2001)
"Bone resorption was assessed by measurement of urinary collagen crosslinks."2.70Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease. ( Coleman, RE; Heatley, S; Herling, C; Jagdev, SP; Purohit, P, 2001)
"Pamidronate was well tolerated in the majority of the patients both during the first six infusions and during the whole study period."2.70The role of disodium pamidronate in the management of bone pain due to malignancy. ( Boffi, R; Brunelli, C; Cazzaniga, M; De Conno, F; Groff, L; Panzeri, C; Ripamonti, C; Zecca, E, 2001)
"Pamidronate treatment also did not have any influence on patient survival or on the frequency of hypercalcaemia."2.69Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group. ( Abildgaard, N; Brincker, H; Ford, J; Gimsing, P; Hedenus, M; Kandra, A; Turesson, I; Westin, J, 1998)
"Pamidronate is a bisphosphonate whose short-term biological efficacy in Paget's disease of bone was convincingly established many years ago."2.69Effect of multiple intravenous pamidronate courses in Paget's disease of bone. ( Arlot, M; Meunier, PJ; Thevenon, J; Trombetti, A; Uebelhart, B, 1999)
"We have evaluated the value of specific bone resorption markers in monitoring metastatic bone disease to define the duration of action of a single high-dose pamidronate infusion."2.68Metabolic effects of pamidronate in patients with metastatic bone disease. ( Coleman, RE; Eastell, R; Guo, CY; Purohit, OP; Vinholes, J, 1996)
" In a randomized phase III trial of 377 patients with multiple myeloma, Aredia was administered in a dosage of 90 mg i."2.68The role of bisphosphonates in the treatment of bone metastases--the U.S. experience. ( Harvey, HA; Lipton, A, 1996)
"Pamidronate is a safe, welltolerated, and effective treatment for Paget's disease."2.68Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study. ( Bhagat, CI; Gutteridge, DH; Kent, GN; Nicholson, GC; Price, RI; Prince, RL; Retallack, RW; Stewart, GO; Stuckey, BG; Thompson, RI; Ward, LC, 1996)
"Pamidronate is a second generation bisphosphonate that has been used in Europe for the treatment of Paget's disease of bone for several years."2.67Effects of intravenous pamidronate therapy on Paget's disease of bone. ( Bombassei, GJ; Raisz, LG; Yocono, M, 1994)
" We have evaluated the effectiveness of three dosage regimes of aminohydroxypropylidene bisphosphonate (pamidronate) in 15 patients with extensive Paget's disease who had become refractory to conventional therapy."2.67Pamidronate is effective for Paget's disease of bone refractory to conventional therapy. ( Gunasekera, RD; Wimalawansa, SJ, 1993)
"There was a significant reduction in pathological fractures and severe bone pain in the APD group, and hypercalcaemia was prevented."2.66Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. ( Beex, LV; Bijvoet, OL; Cleton, FJ; Elte, JW; Harinck, HI; Hermans, J; Kroon, HM; Neijt, JP; van Holten-Verzantvoort, AT; Vermey, P, 1987)
"Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer."2.52Pharmacological interventions for pain in children and adolescents with life-limiting conditions. ( Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V, 2015)
"Pamidronate is an easy to use potent inhibitor of osteolysis, given in conjunction with standard anticancer therapies effectively relieves bone pain and improves performance status."2.41[Pamidronate in the treatment of bone metastases from breast cancer]. ( Gyuricska, A; Landherr, L; Nagykálnai, T; Zatkóné, GP, 2002)
"Management of ankylosing spondylitis (AS) is challenged by the progressive nature of the disease."2.41Conventional treatments for ankylosing spondylitis. ( Brandt, J; Dijkmans, B; Dougados, M; Khan, M; Maksymowych, W; van der Linden, S, 2002)
"Zoledronic acid (4 mg) has been compared to placebo in a randomized Phase III trial involving 422 men with hormone-refractory prostate cancer metastatic to bone."2.41The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. ( Gleason, D; Gordon, D; Kowalski, MO; Lipton, A; Reitsma, D; Rosen, L; Saad, F; Seaman, J; Small, E; Smith, M, 2002)
"Myelomatosis is associated with considerable skeletal morbidity, particularly bone pain and fractures."2.41Bisphosphonates in multiple myeloma. ( Kanis, JA; McCloskey, EV, 2000)
"Patients with breast cancer associated solely with osseous metastasis may live for a number of years."2.41Treatment of metastatic bone disease in breast cancer: bisphosphonates. ( Bastert, G; Diel, IJ; Solomayer, EF, 2000)
"Tramadol is a centrally acting analgesic drug; it has an agonist effect on mu 1 receptors of opioids and acts also by inhibiting the re-uptake of noradrenaline and serotonine which activates descending monoaminergic inhibitory pathways."2.40[Treatment of pain in oncology]. ( De Conno, F; Polastri, D, 1997)
"Pamidronate is a second-generation aminobisphosphonate that is a much more potent inhibitor of osteoclastic activity."2.40Bisphosphonates and breast carcinoma. ( Lipton, A, 1997)
"Experts in the field were approached."2.40Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. ( Bloomfield, DJ, 1998)
"The variability of different breast cancers in the susceptibility to metastatic bone disease is poorly understood."2.39Rationale for the use of bisphosphonates in breast cancer. ( Kanis, JA, 1996)
"Treatment with pamidronate is beneficial for the patient, family and society, increases mobility and bone density, improves quality of life and reduces family dependence in children with OI."1.46Therapy with pamidronate in children with osteogenesis imperfecta. ( Brad, GF; Mang, N; Marginean, O; Mozos, I; Tamasanu, RC, 2017)
"In total, 55,864 women with breast cancer were included, with 307,467 person-years of follow-up."1.35Use of intravenous bisphosphonates in older women with breast cancer. ( Duan, Z; Fang, S; Giordano, SH; Goodwin, JS; Hortobagyi, GN; Kuo, YF, 2008)
"Pamidronate treatment (60 mg/day for 3 days) was repeated in patients without evidence of PDB remission at day 120."1.32Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates. ( Mossetti, G; Nunziata, V; Rendina, D; Sorrentino, M; Viceconti, R, 2004)
"Zoledronic acid also attenuated mechanical hyperalgesia associated with chronic peripheral neuropathy and inflammation in the rat."1.31Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. ( Bowes, M; Chan, O; Fox, AJ; Glatt, M; Green, J; Kesingland, A; Kidd, BL; McNair, K; Medhurst, SJ; Patel, S; Urban, LA; Walker, K, 2002)
"Pamidronate was the most popular choice of drug, but a number of respondents chose to use clodronate, often on the basis of cost saving."1.31Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK. ( Johnson, IS, 2001)
"Treatment with pamidronate, an inhibitor of osteoclastic bone resorption, given every 2 weeks by i."1.31Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. ( Naito, Y; Sakurai, T; Suzuma, T; Tamaki, T; Umemura, T; Yoshimasu, T; Yoshimura, G, 2001)
"To find an effective symptomatic treatment for osteogenesis imperfecta (OI)."1.31Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. ( Aström, E; Söderhäll, S, 2002)
"The baseline levels of bone resorption markers were used to predict the probability of non-progressive bone disease or reduction in pain intensity during bisphosphonate therapy."1.30Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease. ( Engler, H; Koeberle, D; Riesen, WF; Senn, HJ; Thuerlimann, B, 1998)

Research

Studies (138)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.72)18.7374
1990's50 (36.23)18.2507
2000's71 (51.45)29.6817
2010's13 (9.42)24.3611
2020's3 (2.17)2.80

Authors

AuthorsStudies
Bai, Z1
Wang, J1
Kang, M1
Guo, P1
Wang, D1
Bo, Z1
Jian, Y1
Yan, L1
Gangfeng, G1
Xiaojing, L1
Xiaolan, L1
Zhao, C1
Ke, H1
Yang, F1
Maoxia, L1
Jian, W1
Fraleigh, R1
Wei, XC1
Yu, W1
Miettunen, PM1
Marginean, O1
Tamasanu, RC1
Mang, N1
Mozos, I1
Brad, GF1
Van Poznak, C1
Somerfield, MR1
Moy, B1
Lee, KC1
Ferguson, BM1
Abdelaziz, DM1
Stone, LS1
Komarova, SV1
Addison, CL1
Bouganim, N1
Hilton, J1
Vandermeer, L1
Dent, S1
Amir, E1
Hopkins, S1
Kuchuk, I1
Segal, R1
Song, X1
Gertler, S1
Mazzarello, S1
Dranitsaris, G3
Ooi, D1
Pond, G1
Clemons, M2
Beecham, E1
Candy, B1
Howard, R1
McCulloch, R1
Laddie, J1
Rees, H1
Vickerstaff, V1
Bluebond-Langner, M1
Jones, L1
Liao, M1
Magcalas, P1
Hopkins-Braddock, P1
Amin, NL1
James, RM1
Phillips, R1
Giordano, SH1
Fang, S1
Duan, Z1
Kuo, YF1
Hortobagyi, GN3
Goodwin, JS1
Osanai, T1
Tsuchiya, T1
Sugawara, M1
Slobodin, G1
Rosner, I1
Feld, J1
Rimar, D1
Rozenbaum, M1
Boulman, N1
Odeh, M1
Howe, W1
Davis, E1
Valentine, J1
Kotecha, RS1
Powers, N1
Lee, SJ1
Murray, KJ1
Carter, T1
Cole, C1
Heras, P1
Hatzopoulos, A1
Heras, V1
Kritikos, N1
Karagiannis, S1
Kritikos, K1
Weinstein, E1
Arnold, RM1
Joerger, M1
Templeton, A1
Köberle, D1
Engler, H2
Riesen, WF2
Thürlimann, B2
Matarazzo, P2
Lala, R2
Masi, G1
Andreo, M2
Altare, F1
de Sanctis, C2
Nagykálnai, T1
Landherr, L1
Zatkóné, GP1
Gyuricska, A1
Dougados, M1
Dijkmans, B1
Khan, M1
Maksymowych, W1
van der Linden, S1
Brandt, J1
Pistevou-Gombaki, K2
Eleftheriadis, N1
Sofroniadis, I1
Makris, P1
Kouloulias, V1
Lipton, A7
Small, E1
Saad, F1
Gleason, D1
Gordon, D1
Smith, M1
Rosen, L1
Kowalski, MO2
Reitsma, D1
Seaman, J2
Leng, Y1
Chen, SL1
Shi, HZ1
Petcu, EB1
Schug, SA1
Smith, H1
Walker, K1
Medhurst, SJ1
Kidd, BL1
Glatt, M1
Bowes, M1
Patel, S1
McNair, K1
Kesingland, A1
Green, J1
Chan, O1
Fox, AJ1
Urban, LA1
Major, PP1
Cook, R1
Fraunfelder, FW1
Fraunfelder, FT1
Jensvold, B1
Robinson, C1
Baker, N1
Noble, J1
King, A1
David, G1
Sillence, D2
Hofman, P1
Cundy, T2
Myers, B1
Plotkin, H2
Rauch, F1
Zeitlin, L1
Munns, C2
Travers, R2
Glorieux, FH2
Small, EJ1
Smith, MR1
Seaman, JJ4
Petrone, S1
Kelly, WK1
Steineck, G1
Vasireddy, S1
Talwalkar, A1
Miller, H1
Mehan, R1
Swinson, DR1
Walsh, JP1
Ward, LC2
Stewart, GO2
Will, RK1
Criddle, RA1
Prince, RL2
Stuckey, BG2
Dhaliwal, SS1
Bhagat, CI2
Retallack, RW2
Kent, GN2
Drury, PJ1
Vasikaran, S1
Gutteridge, DH2
Rendina, D1
Mossetti, G1
Viceconti, R1
Sorrentino, M1
Nunziata, V1
Kouloulias, VE1
Kouvaris, JR1
Mystakidou, K1
Varela, MN1
Kokakis, J1
Balafouta, M1
Gennatas, C1
Vlahos, LJ1
Chapurlat, RD2
Hugueny, P1
Delmas, PD4
Meunier, PJ6
Kerrison, C1
Davidson, JE1
Cleary, AG1
Beresford, MW1
Díaz, C1
Soutelo, MJ1
Quiroga, L1
Palmer, L1
Lutfi, R1
Perkins, P1
Curtin, NJ1
Green, AR1
Booth, S1
Wang, DJ1
Liu, HQ1
Ren, J1
Chen, YL1
Zhan, QY1
Cai, Y1
Liu, MZ1
Zacharin, M2
Kanumakala, S1
Tanvetyanon, T1
Allington, N1
Vivegnis, D1
Gerard, P1
Liang, JG1
Jiang, NY1
DU, JQ1
Lu, XP1
Liu, XG1
Chen, SX1
Laroche, M1
Cantogrel, S1
Jamard, B1
Constantin, A1
Zabraniecki, L1
Cantagrel, A1
Mazières, B1
Nguyen, T1
Zacharin, MR1
Bayram, F1
Tanriverdi, F1
Kurtoğlu, S1
Atabek, ME1
Kula, M1
Kaynar, L1
Keleştimur, F1
Marzari, D1
Bellone, J1
Corrias, A1
Bender, T1
Donáth, J1
Barna, I1
Gergely, P1
Poór, G1
Bhansali, A1
Singh, R1
Sriraam, M1
Bhadada, S1
Clemons, MJ1
Ooi, WS1
Yogendran, G1
Sukovic, T1
Wong, BY1
Verma, S1
Pritchard, KI1
Trudeau, M1
Cole, DE2
Ooi, W1
Löwing, K1
Aström, E2
Oscarsson, KA1
Söderhäll, S2
Eliasson, AC1
Merlotti, D1
Gennari, L1
Martini, G1
Valleggi, F1
De Paola, V1
Avanzati, A1
Nuti, R1
Poujol, D1
Ristori, JM1
Dubost, JJ1
Soubrier, M1
George, R1
Hephzibah, J1
John, S1
Yamada, K1
Kohno, N1
Gleeson, H1
Wiltshire, E1
Briody, J1
Hall, J1
Chaitow, J1
Cowell, C1
Glover, D1
Keller, A2
Miller, AA1
Browning, S1
Fram, RJ1
George, S2
Zelenakas, K1
Macerata, RS1
Siris, ES1
Chakravarty, K1
Merry, P1
Scott, DG1
Liens, D2
Bombassei, GJ1
Yocono, M1
Raisz, LG1
Purohit, OP4
Anthony, C1
Radstone, CR1
Owen, J1
Coleman, RE6
Morant, R1
Jungi, WF1
Radziwill, A1
Wimalawansa, SJ1
Gunasekera, RD1
Costa, L1
Moreira, C1
da Costa, EB1
Berenson, JR2
Lichtenstein, A1
Porter, L2
Dimopoulos, MA1
Bordoni, R1
Ballester, O1
Kovacs, MJ1
Blacklock, HA1
Bell, R1
Simeone, J2
Reitsma, DJ3
Heffernan, M3
Knight, RD3
Kanis, JA5
Vinholes, J1
Guo, CY1
Eastell, R1
Harvey, HA1
Cascinu, S1
Casadei, V1
Del Ferro, E1
Alessandroni, P1
Catalano, G1
Collange, C1
Brantus, JF1
Sidot, C1
Paterson, AH2
Powles, TJ1
McCloskey, E1
Hanson, J1
Ashley, S1
Price, RI1
Thompson, RI1
Nicholson, GC1
Body, JJ4
Piccart, M1
McBride, G1
Marshall, A1
Kavanagh, RT1
Crisp, AJ1
Strang, P1
Hultborn, R1
Gundersen, S1
Rydén, S1
Holmberg, E1
Carstensen, J1
Wallgren, UB1
Kilany, S1
De Conno, F2
Polastri, D1
Weinstein, RS1
Ciana, G1
Cuttini, M1
Bembi, B1
Vinholes, JJ1
Zekri, J1
Theriault, RL3
Bloomfield, DJ1
Brincker, H1
Westin, J1
Abildgaard, N1
Gimsing, P1
Turesson, I1
Hedenus, M1
Ford, J2
Kandra, A2
Blayney, D1
Sinoff, C1
Wheeler, H1
Simeone, JF1
Mellars, K2
Bishop, NJ1
Chabot, G1
Lanoue, G1
Houston, S1
Rubens, RD2
Haworth, CS2
Selby, PL2
Webb, AK2
Mawer, EB1
Adams, JE2
Freemont, TJ2
Bartl, R1
Burckhardt, P1
Diel, IJ2
Fleisch, H1
Kyle, RA1
Mundy, GR1
Koeberle, D2
Thuerlimann, B2
Senn, HJ2
Bacchus, L1
Chapurlat, R1
Teramoto, S1
Matsuse, T1
Ouchi, Y1
Lortholary, A1
Jadaud, E1
Berthaud, P1
Barişta, I1
Trombetti, A1
Arlot, M1
Thevenon, J1
Uebelhart, B1
Paule, B1
Clerc, D1
Brion, N1
Abdulla, AJ1
McCloskey, EV1
Olson, KB1
Pienta, KJ1
Guillot, M1
Eckart, P1
Desrosieres, H1
Amiour, M1
al-Jazayri, Z1
Bonabello, A1
Galmozzi, MR1
Bruzzese, T1
Zara, GP1
Johnson, IS1
Mishra, A1
Wong, L1
Jonklaas, J1
Vitale, G1
Fonderico, F1
Martignetti, A1
Caraglia, M1
Ciccarelli, A1
Nuzzo, V1
Abbruzzese, A1
Lupoli, G1
Bileckot, R1
Touazi, S1
Auvinet, B1
Le Lain, JC1
Coinde, E1
David, L1
Cottalorda, J1
Allard, D1
Bost, M1
Lucht, F1
Stéphan, JL1
Arzoo, K1
Sadeghi, S1
Pullarkat, V1
Mercadante, S1
Villari, P1
Ferrera, P1
Dabbene, M1
Suzuma, T1
Sakurai, T1
Yoshimura, G1
Umemura, T1
Tamaki, T1
Yoshimasu, T1
Naito, Y1
Jagdev, SP1
Purohit, P1
Heatley, S1
Herling, C1
Egeler, RM1
Brown, RE1
Solomayer, EF1
Bastert, G1
Maksymowych, WP1
Jhangri, GS1
Fitzgerald, AA1
LeClercq, S1
Chiu, P1
Yan, A1
Skeith, KJ1
Aaron, SL1
Homik, J1
Davis, P1
Sholter, D1
Russell, AS1
Ciepłuch, H1
Baran, W1
Hellmann, A1
Groff, L1
Zecca, E1
Brunelli, C1
Boffi, R1
Panzeri, C1
Cazzaniga, M1
Ripamonti, C1
Wong, R1
Wiffen, PJ1
Ryan, PJ1
Gibson, T1
Fogelman, I1
van Holten-Verzantvoort, AT2
Zwinderman, AH1
Aaronson, NK1
Hermans, J2
van Emmerik, B1
van Dam, FS1
van den Bos, B1
Bijvoet, OL2
Cleton, FJ2
Kroon, HM1
Harinck, HI1
Vermey, P1
Elte, JW1
Neijt, JP1
Beex, LV1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression[NCT02313727]Phase 430 participants (Anticipated)Interventional2014-12-31Not yet recruiting
A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420]Phase 14 participants (Actual)Interventional2005-12-31Completed
A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome[NCT00001728]Phase 240 participants (Actual)Interventional1998-08-24Completed
Bone Biopsy for Histomorphometry and Analysis of Bone Marrow Derived Osteoblast and Osteoclast Progenitors to Explore Mechanisms of Decreased Bone Mineral Density in Depression[NCT00001916]17 participants Observational1999-03-31Completed
Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.[NCT01812551]Phase 3171 participants (Actual)Interventional2002-10-31Completed
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation[NCT02074631]Phase 280 participants (Actual)Interventional2015-02-28Completed
A 1-year, Multicenter, Open-label Extension to CZOL446H2337 to Evaluate Safety and Efficacy of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids[NCT01197300]Phase 325 participants (Actual)Interventional2010-10-25Completed
Prophylactic Radiotherapy of MInimally Symptomatic Spinal Disease (PROMISSeD Trial)[NCT05534321]Phase 1/Phase 274 participants (Anticipated)Interventional2022-08-29Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With New Morphometric Vertebral Fractures During the 12 Month Extension Period by Core Treatment Group.

Vertebral morphometry (or concave index) was calculated using the average ratio between mid-height and posterior height from L1 to L4 and performed by a central reader. A new morphometric vertebral fractures during the 12 month Extension Period was defined as a morphometric vertebral fracture present at Month 24 X-ray which was not present at the Extension Baseline (Baseline 2). (NCT01197300)
Timeframe: Month 24 (Visit 15/Final Extension Visit)

InterventionParticipants (Count of Participants)
Core Treatment Zoledronic Acid1
Core Treatment: Placebo1

Number of Participants With New Vertebral Fractures During the 12 Month Extension Period by Core Treatment Group.

New vertebral fractures are defined as fractures of Genant grade 1 or higher that occur at lumbar or thoracic spine from first extension dose infusion to the end of the study in a previously normal vertebra. (NCT01197300)
Timeframe: Month 24 (Visit 15/Final Extension Visit)

InterventionParticipants (Count of Participants)
Core Treatment Zoledronic Acid1
Core Treatment: Placebo1

Long-term Safety of Zoledronic Acid for the Treatment of Osteoporotic Children Treated With Glucocorticoids.

Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that zoledronic acid given long-term, over an additional 12 months from the Core study (CZOL446H2337), is safe for the treatment of osteoporotic children treated with glucocorticoids through the monitoring of relevant clinical and laboratory safety parameters. (NCT01197300)
Timeframe: Baseline 1 (Visit 1 of the Core Study) through Month 24 (Visit 15/Final Extension Visit)

,
InterventionParticipants (Count of Participants)
On-treatment Adverse Events (AEs)On-treatment Serious Adverse Events (SAEs)On-treatment Deaths
Core Treatment Zoledronic Acid730
Core Treatment: Placebo1200

Mean Change From Baseline (Core and Extension) in 2nd Metacarpal Cortical Width at Month 24 by Core Treatment Group.

Left postero-anterior (PA) hand/wrist X-ray were taken at the final visit of Core study and at Visit 15/EOS (Month 24) to assess bone age. The change in 2nd metacarpal cortical width at Month 24 relative to the respective Baseline was calculated. If a fracture of the left upper extremity precluded radiographic imaging, (or precluded this X-ray in the Core study) then the right hand was evaluated for this purpose. In this case, an image of the right hand was carried out at both Visit 8 and at Visit 15/EOS (Month 24). The information was used in the assessment of bone density. (NCT01197300)
Timeframe: Baseline 1 (Visit 1 of the Core Study) and Baseline 2 (Visit 9 of the Extension Study) through Month 24 (Visit 15/Final Extension Visit)

,
Interventionmillimeter (mm) (Least Squares Mean)
2nd metacarpal cortical width change from BL12nd metacarpal cortical width change from BL2
Core Treatment Zoledronic Acid-0.04-0.09
Core Treatment: Placebo-0.030.02

Mean Change From Baseline 1 (Visit 1 of the Core Study) in BSAP at Month 18 and 24 by Core Treatment Group.

Bone specific alkaline phosphatase (BSAP) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)

,
Interventionnanogram per milliliter (ng/mL) (Least Squares Mean)
BSAP Change at Month 18BSAP Change at Month 24
Core Treatment Zoledronic Acid-13.716-9.675
Core Treatment: Placebo3.975-6.013

Mean Change From Baseline 1 (Visit 1 of the Core Study) in Lumbar Spine Bone Mineral Content (BMC) at Month 18 and 24 by Core Treatment Group.

Lumbar Spine Bone Mineral Content (BMC) was determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure BMC were described in the respective DXA Manuals. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)

,
Interventiongram (Least Squares Mean)
Lumbar Spine BMC Change at Month 18Lumbar Spine BMC Change at Month 24
Core Treatment Zoledronic Acid12.29315.845
Core Treatment: Placebo9.93314.666

Mean Change From Baseline 1 (Visit 1 of the Core Study) in Lumbar Spine Bone Mineral Density (BMD) Z-score at Month 18 and 24 by Core Treatment Group.

Lumbar Spine Bone Mineral Density (BMD) Z-score was determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure Lumbar Spine BMD Z-score were described in the respective DXA Manuals provided by central imaging vendor. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)

,
InterventionZ-score (Least Squares Mean)
Lumbar Spine BMD Z-score Change at Month 18Lumbar Spine BMD Z-score Change at Month 24
Core Treatment Zoledronic Acid-40.648-46.161
Core Treatment: Placebo-44.348-67.913

Mean Change From Baseline 1 (Visit 1 of the Core Study) in Serum NTX at Month 18 and 24 by Core Treatment Group.

Serum Cross linked N-telopeptide (NTX) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)

,
Interventionnmol BCE/L (Least Squares Mean)
Serum NTX Change at Month 18Serum NTX Change at Month 24
Core Treatment Zoledronic Acid-17.577-17.450
Core Treatment: Placebo-12.916-14.891

Mean Change From Baseline 1 (Visit 1 of the Core Study) in Serum P1NP at Month 18 and 24 by Core Treatment Group.

Serum Procollagen type 1 amino-terminal propeptide (P1NP) was collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)

,
Interventionnanogram per milliliter (ng/mL) (Least Squares Mean)
Serum P1NP Change at Month 18Serum P1NP Change at Month 24
Core Treatment Zoledronic Acid-169.837-228.068
Core Treatment: Placebo-22.157-95.631

Mean Change From Baseline 1 (Visit 1 of the Core Study) in Serum TRAP-5b at Month 18 and 24 by Core Treatment Group.

Serum Tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were collected at the final visit Core study at Visit 8, or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension study Visit/EOS) of Extension study according to the instructions provided in the Laboratory Manual. The samples were analyzed in batches at the laboratory. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. Decrease or negative changes from Core baseline indicated a pharmacological response to therapy. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)

,
InterventionU/L (Least Squares Mean)
Serum TRAP-5b Change at Month 18Serum TRAP-5b Change at Month 24
Core Treatment Zoledronic Acid-2.661-2.670
Core Treatment: Placebo-1.179-2.260

Mean Change From Baseline 1 (Visit 1 of the Core Study) in Total Body BMC at Month 18 and 24 by Core Treatment Group.

Total body BMC were determined by the central imaging vendor at the final visit of Core study (Visit 8) or at 1st infusion visit (Visit 9), and thereafter at Visit 12 (Month 18) and Visit 15 (Month 24) (final Extension Study visit/EOS) of Extension study. The methods to be used to measure BMC were described in the respective DXA Manuals. Positive changes from Core baseline indicated an improvement in condition. (NCT01197300)
Timeframe: Month 18 (Visit 12 of the Extension Study), Month 24 (Visit 15/Final Extension Visit)

,
Interventiongram (Least Squares Mean)
Total body BMC Change at Month 18Total body BMC Change at Month 24
Core Treatment Zoledronic Acid387.721496.997
Core Treatment: Placebo266.592431.323

Percentage of Patients With Reduction in Pain From Baseline 1 (Visit 1 of the Core Study) at Month 15, 18, 21 and 24 by Core Treatment Group.

Pain was evaluated at each visit (at office and telephone visit) at the final visit of the Core study and first visit of the Extension study (Visit 9), Visits 11 (Month 15), 12 (Month 18), 14 (Month 21) and 15 (Month 24) using the Faces Pain Scale-Revised (FPS-R). Children were selecting the face that best fits their pain. The pain score ranged from 0 (No Pain) to 10 (Very Much Pain). The reduction in pain from Core baseline by visit was evaluated based on whether or not patients had a decrease in their FPS-R from baseline. If pain remained the same or worsened from baseline a patient was classified as '0' and if the pain scale decreased then the patient was classified as '1'. (NCT01197300)
Timeframe: Month 15, Month 18, Month 21, Month 24

,
InterventionPercentage of Patients (Number)
Reduction in Pain at Month 15Reduction in Pain at Month 18Reduction in Pain at Month 21Reduction in Pain at Month 24
Core Treatment Zoledronic Acid55.630.030.030.0
Core Treatment: Placebo46.250.050.038.5

Reviews

23 reviews available for pamidronate and Pain

ArticleYear
Pharmacotherapies for Central Post-Stroke Pain: A Systematic Review and Network Meta-Analysis.
    Oxidative medicine and cellular longevity, 2022, Volume: 2022

    Topics: Anticonvulsants; Etanercept; Humans; Lamotrigine; Levetiracetam; Network Meta-Analysis; Pain; Pamidr

2022
Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
    The Cochrane database of systematic reviews, 2015, Mar-13, Issue:3

    Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool

2015
QUESTION 1: Should we be using bisphosphonates for osteonecrosis complicating childhood acute lymphoblastic leukaemia?
    Archives of disease in childhood, 2016, Volume: 101, Issue:3

    Topics: Adolescent; Alendronate; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Fe

2016
Pamidronate treatment in rheumatology practice: a comprehensive review.
    Clinical rheumatology, 2009, Volume: 28, Issue:12

    Topics: Anti-Inflammatory Agents; Diphosphonates; Humans; Pain; Pamidronate; PubMed; Randomized Controlled T

2009
[Pamidronate in the treatment of bone metastases from breast cancer].
    Magyar onkologia, 2002, Volume: 46, Issue:3

    Topics: Ambulatory Care; Animals; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; D

2002
Conventional treatments for ankylosing spondylitis.
    Annals of the rheumatic diseases, 2002, Volume: 61 Suppl 3

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antimalarials; Azathioprine; Dipho

2002
The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate.
    Cancer investigation, 2002, Volume: 20 Suppl 2

    Topics: Adenocarcinoma; Biomarkers; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosphonat

2002
Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
    American journal of clinical oncology, 2002, Volume: 25, Issue:6 Suppl 1

    Topics: Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Data Interpretation, Statistical; Diphosphonates;

2002
[Clinical study of bisphosphonates for bone metastasis in breast cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2007, Nov-28, Volume: 65 Suppl 9

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fracture

2007
Bone and cancer: pathophysiology and treatment of metastases.
    Bone, 1995, Volume: 17, Issue:2 Suppl

    Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Diseases, Metabolic; Bone Neoplasms; Breast Neoplasms

1995
Use of bisphosphonates in cancer patients.
    Cancer treatment reviews, 1996, Volume: 22, Issue:4

    Topics: Alendronate; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodronic Acid; Diphosphonates; Etid

1996
Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article.
    Acta oncologica (Stockholm, Sweden), 1996, Volume: 35 Suppl 5

    Topics: Analgesia; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonate

1996
Rationale for the use of bisphosphonates in breast cancer.
    Acta oncologica (Stockholm, Sweden), 1996, Volume: 35 Suppl 5

    Topics: Bone Neoplasms; Bone Remodeling; Breast Neoplasms; Clodronic Acid; Cost-Benefit Analysis; Diphosphon

1996
[Treatment of pain in oncology].
    Tumori, 1997, Volume: 83, Issue:2 Suppl

    Topics: Administration, Cutaneous; Analgesics, Opioid; Anesthetics, Dissociative; Diphosphonates; Fentanyl;

1997
Bisphosphonates and breast carcinoma.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Diseases; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcification, Physiologic; Clinic

1997
Bisphosphonates in multiple myeloma.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye

1997
Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:3

    Topics: Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonates; Evidence

1998
Current use of bisphosphonates in oncology. International Bone and Cancer Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:12

    Topics: Analgesics, Non-Narcotic; Bone and Bones; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clodron

1998
[Bisphosphonates and bone metastases].
    Bulletin du cancer, 1999, Volume: 86, Issue:9

    Topics: Antineoplastic Agents; Bone Diseases; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; Diphosphonat

1999
Bisphosphonates in multiple myeloma.
    Cancer, 2000, Jun-15, Volume: 88, Issue:12 Suppl

    Topics: Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Hypercalcemia; Multiple Myeloma; Pain; Pamid

2000
Treatment of metastatic bone disease in breast cancer: bisphosphonates.
    Clinical breast cancer, 2000, Volume: 1, Issue:1

    Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D

2000
Bisphosphonates for the relief of pain secondary to bone metastases.
    The Cochrane database of systematic reviews, 2002, Issue:2

    Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Clodronic Acid; Diphosphonates; Eti

2002
Bone metastases and tumor-induced hypercalcemia.
    Current opinion in oncology, 1992, Volume: 4, Issue:4

    Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Calcitonin; Combined Modality Therapy; Dipho

1992

Trials

53 trials available for pamidronate and Pain

ArticleYear
A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.
    Breast cancer research and treatment, 2014, Volume: 144, Issue:3

    Topics: Administration, Intravenous; Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Ne

2014
Use of bisphosphonates for the treatment of osteonecrosis as a complication of therapy for childhood acute lymphoblastic leukaemia (ALL).
    Pediatric blood & cancer, 2010, Jul-01, Volume: 54, Issue:7

    Topics: Administration, Oral; Adolescent; Adrenal Cortex Hormones; Alendronate; Antineoplastic Combined Chem

2010
A comparative study of intravenous ibandronate and pamindronate in patients with bone metastases from breast or lung cancer: effect on metastatic bone pain.
    American journal of therapeutics, 2011, Volume: 18, Issue:5

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Diphosphonates;

2011
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:5

    Topics: Aged; Antineoplastic Agents; Biomarkers; Bone and Bones; Bone Neoplasms; Collagen Type I; Diphosphon

2011
Pamidronate treatment in bone fibrous dysplasia in children and adolescents with McCune-Albright syndrome.
    Journal of pediatric endocrinology & metabolism : JPEM, 2002, Volume: 15 Suppl 3

    Topics: Adolescent; Adult; Alkaline Phosphatase; Body Height; Bone and Bones; Bone Density; Child; Diphospho

2002
[Effects of pamidronate disodium (Bonin) combined with chemotherapy on bone pain in multiple myeloma].
    Hang tian yi xue yu yi xue gong cheng = Space medicine & medical engineering, 2002, Volume: 15, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Bone Diseases; Clinical Trials as Topic; Diphosphonates; Drug Th

2002
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-01, Volume: 21, Issue:23

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind

2003
A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Bone, 2004, Volume: 34, Issue:4

    Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone and Bones; Calcium;

2004
Duration of bisphosphonate treatment: results of a non-randomised study in patients previously treated with local irradiation for bone metastases from breast cancer.
    Current medical research and opinion, 2004, Volume: 20, Issue:6

    Topics: Adult; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Greece; Huma

2004
[Pamidronate in treatment of pain caused by bone metastasis].
    Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:11 Suppl

    Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Fem

2004
Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
    Journal of pediatric endocrinology & metabolism : JPEM, 2004, Volume: 17, Issue:11

    Topics: Absorptiometry, Photon; Adolescent; Alkaline Phosphatase; Body Height; Body Weight; Bone and Bones;

2004
Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study.
    Acta orthopaedica Belgica, 2005, Volume: 71, Issue:1

    Topics: Adolescent; Anti-Inflammatory Agents; Cerebral Palsy; Child; Child, Preschool; Diphosphonates; Drug

2005
[Clinical value of combined therapy with 188Re-HEDP and pamidronate in breast cancer with bone metastasis].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:3

    Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoembryonic Antigen; Comb

2005
Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study.
    Clinical rheumatology, 2006, Volume: 25, Issue:5

    Topics: Aged; Aged, 80 and over; Analgesics; Bone Density Conservation Agents; Calcitonin; Diphosphonates; F

2006
Pamidronate treatment of steroid associated osteonecrosis in young patients treated for acute lymphoblastic leukaemia--two-year outcomes.
    Journal of pediatric endocrinology & metabolism : JPEM, 2006, Volume: 19, Issue:2

    Topics: Adolescent; Adult; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Diphosphonates

2006
Bisphosphonate treatment of bone fibrous dysplasia in McCune-Albright syndrome.
    Journal of pediatric endocrinology & metabolism : JPEM, 2006, Volume: 19 Suppl 2

    Topics: Adolescent; Alkaline Phosphatase; Bone Density Conservation Agents; Child; Child, Preschool; Diphosp

2006
The analgesic effect of pamidronate is not caused by the elevation of beta endorphin level in Paget's disease--a controlled pilot study.
    Neuro endocrinology letters, 2006, Volume: 27, Issue:4

    Topics: Aged; Analgesics; beta-Endorphin; Bone Density Conservation Agents; Diphosphonates; Female; Humans;

2006
Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-20, Volume: 24, Issue:30

    Topics: Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Br

2006
A Phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy.
    Breast cancer research and treatment, 2008, Volume: 108, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density Conservation Agen

2008
Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2007, Volume: 22, Issue:10

    Topics: Aged; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Hu

2007
Efficacy of pamidronate in erosive degenerative disk disease: A pilot study.
    Joint bone spine, 2007, Volume: 74, Issue:6

    Topics: Adult; Anti-Inflammatory Agents; Diphosphonates; Female; Humans; Infant; Intervertebral Disc Displac

2007
Does pamidronate enhance the analgesic effect of radiotherapy? A randomized trial.
    Palliative medicine, 2007, Volume: 21, Issue:8

    Topics: Analgesia; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Pain; Pain Measurement; Pa

2007
Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
    Cancer, 1994, Dec-01, Volume: 74, Issue:11

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Analgesics, Opioid; Bone Neoplasms; Bre

1994
A single infusion of bisphosphonate AHPrBP in the treatment of Paget's disease of bone.
    The Journal of rheumatology, 1994, Volume: 21, Issue:11

    Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Child; Creatinine; Diphosphonates; Female; Humans; Hy

1994
Effects of intravenous pamidronate therapy on Paget's disease of bone.
    The American journal of the medical sciences, 1994, Volume: 308, Issue:4

    Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Calcium; Diphosphonates; Female; Humans; Hydroxyproli

1994
High-dose intravenous pamidronate for metastatic bone pain.
    British journal of cancer, 1994, Volume: 70, Issue:3

    Topics: Bone and Bones; Bone Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Female; Humans; Hy

1994
Pamidronate for pain control in patients with malignant osteolytic bone disease: a prospective dose-effect study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1994, Volume: 2, Issue:1

    Topics: Activities of Daily Living; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relation

1994
Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
    Calcified tissue international, 1993, Volume: 53, Issue:4

    Topics: Alkaline Phosphatase; Calcitonin; Creatinine; Diphosphonates; Drug Administration Schedule; Drug Res

1993
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    The New England journal of medicine, 1996, Feb-22, Volume: 334, Issue:8

    Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H

1996
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    The New England journal of medicine, 1996, Feb-22, Volume: 334, Issue:8

    Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H

1996
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    The New England journal of medicine, 1996, Feb-22, Volume: 334, Issue:8

    Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H

1996
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    The New England journal of medicine, 1996, Feb-22, Volume: 334, Issue:8

    Topics: Aged; Diphosphonates; Disease-Free Survival; Double-Blind Method; Female; Fractures, Bone; Humans; H

1996
Metabolic effects of pamidronate in patients with metastatic bone disease.
    British journal of cancer, 1996, Volume: 73, Issue:9

    Topics: Aged; Alkaline Phosphatase; Analysis of Variance; Biomarkers; Bone Development; Bone Neoplasms; Bone

1996
The role of bisphosphonates in the treatment of bone metastases--the U.S. experience.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1996, Volume: 4, Issue:3

    Topics: Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Clinical Trials as Topic;

1996
Pamidronate in patients with painful bone metastases, who failed initial treatment with hormones and/or chemotherapy.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1996, Volume: 4, Issue:1

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Neoplasms; Diphosphonates;

1996
Clinical, biochemical, hematologic, and radiographic responses in Paget's disease following intravenous pamidronate disodium: a 2-year study.
    Bone, 1996, Volume: 19, Issue:4

    Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Analysis of Variance; Bone and Bones; Diphosphonates;

1996
Efficacy of pamidronate in breast cancer with bone metastases: a randomized double-blind placebo controlled multicenter study.
    Acta oncologica (Stockholm, Sweden), 1996, Volume: 35 Suppl 5

    Topics: Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Humans; Osteolysis; Pain; Pamidronate; Qua

1996
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1997, Volume: 12, Issue:10

    Topics: Adolescent; Adult; Biomarkers; Biopsy; Bone and Bones; Bone Density; Bone Remodeling; Calcium, Dieta

1997
Bisphosphonates in multiple myeloma.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Bone Diseases; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Multiple Mye

1997
High dose pamidronate: clinical and biochemical effects in metastatic bone disease.
    Cancer, 1997, Oct-15, Volume: 80, Issue:8 Suppl

    Topics: Biomarkers, Tumor; Bone Diseases; Breast Neoplasms; Collagen; Diphosphonates; Female; Humans; Male;

1997
Fitting new modalities into practice guidelines.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:11A

    Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Data Interpretation, Statis

1997
Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial. Danish-Swedish co-operative study group.
    British journal of haematology, 1998, Volume: 101, Issue:2

    Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols

1998
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:6

    Topics: Alkaline Phosphatase; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms;

1998
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    The New England journal of medicine, 1998, Oct-01, Volume: 339, Issue:14

    Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C

1998
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    The New England journal of medicine, 1998, Oct-01, Volume: 339, Issue:14

    Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C

1998
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    The New England journal of medicine, 1998, Oct-01, Volume: 339, Issue:14

    Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C

1998
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    The New England journal of medicine, 1998, Oct-01, Volume: 339, Issue:14

    Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C

1998
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    The New England journal of medicine, 1998, Oct-01, Volume: 339, Issue:14

    Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C

1998
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    The New England journal of medicine, 1998, Oct-01, Volume: 339, Issue:14

    Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C

1998
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    The New England journal of medicine, 1998, Oct-01, Volume: 339, Issue:14

    Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C

1998
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    The New England journal of medicine, 1998, Oct-01, Volume: 339, Issue:14

    Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C

1998
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
    The New England journal of medicine, 1998, Oct-01, Volume: 339, Issue:14

    Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Development; Bone Resorption; Calcium; Child; C

1998
A randomised phase II study of oral pamidronate for the treatment of bone metastases from breast cancer.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:6

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Breast

1998
Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis.
    Lancet (London, England), 1998, Nov-28, Volume: 352, Issue:9142

    Topics: Adult; Anti-Inflammatory Agents; Bone Density; Bone Diseases; Cystic Fibrosis; Diphosphonates; Dose-

1998
Pamidronate treatment in patients with malignant osteolytic bone disease and pain: a prospective randomized double-blind trial.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1999, Volume: 7, Issue:1

    Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Analgesics; Anti-Inflammatory Agents; Antine

1999
Effect of multiple intravenous pamidronate courses in Paget's disease of bone.
    Revue du rhumatisme (English ed.), 1999, Volume: 66, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Bone Demineralization, Pathologic; Diphosp

1999
Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Double-Blind Method;

2000
Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer.
    British journal of cancer, 2001, Jun-15, Volume: 84, Issue:12

    Topics: Adenocarcinoma, Follicular; Adult; Aged; Analgesics; Anti-Inflammatory Agents; Bone Neoplasms; Bone

2001
Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:10

    Topics: Administration, Oral; Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Bone Neoplasm

2001
A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis.
    Arthritis and rheumatism, 2002, Volume: 46, Issue:3

    Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Diphosphonates

2002
Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
    Medical science monitor : international medical journal of experimental and clinical research, 2002, Volume: 8, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protoc

2002
The role of disodium pamidronate in the management of bone pain due to malignancy.
    Palliative medicine, 2001, Volume: 15, Issue:4

    Topics: Adult; Aged; Analgesics; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphospho

2001
The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:5

    Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Diphos

1991
Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment.
    Lancet (London, England), 1987, Oct-31, Volume: 2, Issue:8566

    Topics: Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Diphosph

1987

Other Studies

63 other studies available for pamidronate and Pain

ArticleYear
Effects of Pamidronate Disodium Combined with Calcium on BMD Values and Severity of Pain in Elderly Patients with Osteoporosis Based on Mobile Terminal Platform for Internet of Things.
    Disease markers, 2022, Volume: 2022

    Topics: Aged; Bone Density; Calcium; Diphosphonates; Humans; Internet of Things; Lumbar Vertebrae; Osteoporo

2022
Chronic recurrent multifocal osteomyelitis with a comprehensive approach to differential diagnosis of paediatric skull pain.
    BMJ case reports, 2023, Jan-04, Volume: 16, Issue:1

    Topics: Child; Chronic Disease; Diagnosis, Differential; Female; Humans; Magnetic Resonance Imaging; Osteiti

2023
Therapy with pamidronate in children with osteogenesis imperfecta.
    Drug design, development and therapy, 2017, Volume: 11

    Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Child; Child, Pres

2017
Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.
    Journal of oncology practice, 2017, Volume: 13, Issue:12

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Denosumab; Female; Humans; Medic

2017
Elderly man with mandibular pain.
    Emergency medicine journal : EMJ, 2019, Volume: 36, Issue:1

    Topics: Abscess; Aged; Anti-Bacterial Agents; Bone Density Conservation Agents; Drainage; Fever; Humans; Mal

2019
Osteolysis and pain due to experimental bone metastases are improved by treatment with rapamycin.
    Breast cancer research and treatment, 2014, Volume: 143, Issue:2

    Topics: Animals; Antibiotics, Antineoplastic; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, T

2014
Case 4: How Much Is Too Much? A Case of Hypercalcemia in a 6-year-old Boy.
    Pediatrics in review, 2015, Volume: 36, Issue:9

    Topics: Bone Density Conservation Agents; Calcitonin; Child; Diagnosis, Differential; Dietary Supplements; D

2015
Use of intravenous bisphosphonates in older women with breast cancer.
    The oncologist, 2008, Volume: 13, Issue:5

    Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neopl

2008
Rapid pain relief and marked sclerotic change of multiple bone metastases from a synovial sarcoma after treatment with intravenous pamidronate and chemotherapy.
    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association, 2009, Volume: 14, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neopla

2009
Pamidronate improves pain, wellbeing, fracture rate and bone density in 14 children and adolescents with chronic neurological conditions.
    Developmental neurorehabilitation, 2010, Volume: 13, Issue:1

    Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Child; Diphosp

2010
Bisphosphonates for bone pain #113.
    Journal of palliative medicine, 2010, Volume: 13, Issue:7

    Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Humans; Imidazoles; Neopla

2010
Palliative treatment of painful bone metastases from non-Hodgkin lymphoma with disodium pamidronate.
    Journal of experimental & clinical cancer research : CR, 2002, Volume: 21, Issue:3

    Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Humans; Lymp

2002
[Bisphosphonates in bone metastases. Fewer fractures, less pain].
    MMW Fortschritte der Medizin, 2002, Sep-26, Volume: 144, Issue:39

    Topics: Bone Neoplasms; Clinical Trials as Topic; Diphosphonates; Fractures, Spontaneous; Humans; Imidazoles

2002
Clinical evaluation of onset of analgesia using intravenous pamidronate in metastatic bone pain.
    Journal of pain and symptom management, 2002, Volume: 24, Issue:3

    Topics: Analgesia; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Injections, Intravenous; P

2002
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain.
    Pain, 2002, Volume: 100, Issue:3

    Topics: Animals; Bone Density; Bone Neoplasms; Clodronic Acid; Diphosphonates; Female; Hyperalgesia; Hyperes

2002
Scleritis and other ocular side effects associated with pamidronate disodium.
    American journal of ophthalmology, 2003, Volume: 135, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Conjunctivitis; Diphosphonates; Female; Humans; Male

2003
The osteodystrophy of mucolipidosis type III and the effects of intravenous pamidronate treatment.
    Journal of inherited metabolic disease, 2002, Volume: 25, Issue:8

    Topics: Absorptiometry, Photon; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Bone Density; Bone Dise

2002
Comment on systemic mastocytosis study.
    British journal of haematology, 2003, Volume: 121, Issue:3

    Topics: Adult; Diphosphonates; Humans; Interferon-alpha; Male; Mastocytosis, Systemic; Middle Aged; Pain; Pa

2003
Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone.
    The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:10

    Topics: Adolescent; Alkaline Phosphatase; Anti-Inflammatory Agents; Biomarkers; Biopsy; Body Height; Calcium

2003
Bisphosphonates for men with prostate cancer: sifting through the rubble.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-01, Volume: 21, Issue:23

    Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Double-Blind Method; Humans; Male; Pain; Pall

2003
Patterns of pain in Paget's disease of bone and their outcomes on treatment with pamidronate.
    Clinical rheumatology, 2003, Volume: 22, Issue:6

    Topics: Aged; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow

2003
Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Calcified tissue international, 2004, Volume: 75, Issue:3

    Topics: Administration, Oral; Alkaline Phosphatase; Calcitriol; Clodronic Acid; Diphosphonates; Drug Toleran

2004
Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment.
    Bone, 2004, Volume: 35, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling;

2004
Pamidronate in the treatment of childhood SAPHO syndrome.
    Rheumatology (Oxford, England), 2004, Volume: 43, Issue:10

    Topics: Acquired Hyperostosis Syndrome; Adolescent; Anti-Inflammatory Agents; Child; Diphosphonates; Female;

2004
[Treatment of multiple myeloma with intravenous pamidronate. Pain prevention and suppression of hypercalcemia risk].
    Medicina, 2004, Volume: 64, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Diphosphonates; Female; Humans; Hypercalcemia; Injec

2004
Pain from myelofibrosis treated with regular pamidronate.
    British journal of haematology, 2004, Volume: 127, Issue:3

    Topics: Adult; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diphosphonates; Dru

2004
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
    Journal of the National Cancer Institute, 2005, Jan-05, Volume: 97, Issue:1

    Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazol

2005
Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
    Journal of pediatric endocrinology & metabolism : JPEM, 2006, Volume: 19, Issue:3

    Topics: Abnormalities, Multiple; Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Central

2006
Pachydermoperiostitis and bisphosphonates.
    The Journal of the Association of Physicians of India, 2006, Volume: 54

    Topics: Adolescent; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Disease Progression;

2006
Effect of intravenous pamidronate therapy on everyday activities in children with osteogenesis imperfecta.
    Acta paediatrica (Oslo, Norway : 1992), 2007, Volume: 96, Issue:8

    Topics: Absorptiometry, Photon; Adolescent; Bone and Bones; Bone Density; Bone Density Conservation Agents;

2007
Childhood chronic recurrent multifocal osteomyelitis: pamidronate therapy decreases pain and improves vertebral shape.
    The Journal of rheumatology, 2008, Volume: 35, Issue:4

    Topics: Adolescent; Anti-Inflammatory Agents; Bone Density; Child; Child, Preschool; Diphosphonates; Female;

2008
Extensive personal experience: Paget's disease of bone.
    The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:2

    Topics: Animals; Calcitonin; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pain; Pamidronate;

1995
Long-term effects of intravenous pamidronate in fibrous dysplasia of bone.
    Lancet (London, England), 1994, Apr-16, Volume: 343, Issue:8903

    Topics: Adolescent; Adult; Alkaline Phosphatase; Diphosphonates; Female; Fibrous Dysplasia of Bone; Follow-U

1994
[Disodium pamidronate (APD) in the treatment of bone metastases].
    Acta medica portuguesa, 1993, Volume: 6, Issue:2

    Topics: Adult; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Humans; Middle Aged; Multiple Myeloma; Pain

1993
Sapho syndrome with femoral hyperostosis. Two case-reports.
    Revue du rhumatisme (English ed.), 1996, Volume: 63, Issue:5

    Topics: Adult; Antirheumatic Agents; Diphosphonates; Female; Femur; Humans; Hyperostosis; Magnetic Resonance

1996
Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
    The Canadian journal of oncology, 1995, Volume: 5 Suppl 1

    Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Clodronic Acid; D

1995
Treating bone metastases: sparing the patient needless pain.
    Journal of the National Cancer Institute, 1997, Mar-19, Volume: 89, Issue:6

    Topics: Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Pain; Pain Management; Palliative Care; Pam

1997
The effect of pamidronate on lumbar spine bone density and pain in osteoporosis secondary to systemic mastocytosis.
    British journal of rheumatology, 1997, Volume: 36, Issue:3

    Topics: Adult; Bone Density; Diphosphonates; Female; Humans; Lumbar Vertebrae; Male; Mastocytosis; Middle Ag

1997
Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 1997, Volume: 12, Issue:8

    Topics: Adult; Bone Density; Calcium, Dietary; Collagen; Collagen Type I; Diphosphonates; Female; Fibrous Dy

1997
Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement.
    The New England journal of medicine, 1997, Sep-04, Volume: 337, Issue:10

    Topics: Adult; Bone Density; Bone Remodeling; Diphosphonates; Female; Gaucher Disease; Humans; Male; Middle

1997
Diagnostic and prognostic value of biochemical markers in malignant bone disease: a prospective study on the effect of bisphosphonate on pain intensity and progression of malignant bone disease.
    Clinical chemistry and laboratory medicine, 1998, Volume: 36, Issue:11

    Topics: Aged; Amino Acids; Biomarkers; Bone Density; Bone Neoplasms; Bone Resorption; Chromatography, High P

1998
Bisphosphonates for metastatic bone pain.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 1999, Volume: 7, Issue:1

    Topics: Analgesics, Non-Narcotic; Antineoplastic Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms;

1999
The nonsurgical treatment of fibrous dysplasia.
    Revue du rhumatisme (English ed.), 1999, Volume: 66, Issue:1

    Topics: Adolescent; Bone Density; Calcium; Diphosphonates; Ergocalciferols; Female; Fibrous Dysplasia of Bon

1999
Increased cytokines and pamidronate-induced bone pain in adults with cystic fibrosis.
    Lancet (London, England), 1999, Feb-27, Volume: 353, Issue:9154

    Topics: Adult; Anti-Inflammatory Agents; Bone Diseases; Cystic Fibrosis; Diphosphonates; Humans; Pain; Pamid

1999
Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis.
    Lancet (London, England), 1999, May-29, Volume: 353, Issue:9167

    Topics: Adult; Anti-Infective Agents; Bone Diseases; Cystic Fibrosis; Diphosphonates; Glucocorticoids; Human

1999
Biphosphonates and the flare phenomenon.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:4

    Topics: Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Pain

1999
[Biosphonates in oncology].
    Presse medicale (Paris, France : 1983), 2000, Apr-08, Volume: 29, Issue:13

    Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Neoplasms; Osteolysis; Pain

2000
Use of pamidronate for acute pain relief following osteoporotic vertebral fractures.
    Rheumatology (Oxford, England), 2000, Volume: 39, Issue:5

    Topics: Acute Disease; Aged; Aged, 80 and over; Analgesics; Diphosphonates; Female; Humans; Middle Aged; Ost

2000
Osteoporosis pseudoglioma syndrome: treatment of spinal osteoporosis with intravenous bisphosphonates.
    The Journal of pediatrics, 2000, Volume: 137, Issue:3

    Topics: Analgesics, Non-Narcotic; Bone Density; Child; Clodronic Acid; Diphosphonates; Female; Fractures, Bo

2000
Use of bisphosphonates in the treatment of prostate cancer.
    Oncology (Williston Park, N.Y.), 2000, Volume: 14, Issue:9

    Topics: Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Humans; Male; Pain; Palliative Care; Pamidron

2000
[Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2001, Volume: 8, Issue:2

    Topics: Age Factors; Alkaline Phosphatase; Bone Density; Diphosphonates; Drug Administration Schedule; Growt

2001
Analgesic effect of bisphosphonates in mice.
    Pain, 2001, Volume: 91, Issue:3

    Topics: Abdomen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents; Clodronic Acid; Diphosphonates

2001
Use of bisphosphonates for the treatment of metastatic bone pain. A survey of palliative physicians in the UK.
    Palliative medicine, 2001, Volume: 15, Issue:2

    Topics: Bone Neoplasms; Clodronic Acid; Diphosphonates; Drug Costs; Humans; Pain; Palliative Care; Pamidrona

2001
Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism.
    Endocrine, 2001, Volume: 14, Issue:2

    Topics: Antineoplastic Agents; Bone Neoplasms; Calcitonin; Calcium Carbonate; Diphosphonates; Female; Humans

2001
[Analgesic effect of Pamidronate on bone pain in patient with hypertrophic pulmonary osteoarthropathy].
    Revue de pneumologie clinique, 2001, Volume: 57, Issue:3

    Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Squamous Cell; Diphosphonates; Drug Admi

2001
[Chronic recurrent multifocal osteomyelitis in children: report of 17 cases].
    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, 2001, Volume: 8, Issue:6

    Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Bone and Bones; Child; Child, Pr

2001
Pamidronate for bone pain from osteolytic lesions in Langerhans'-cell histiocytosis.
    The New England journal of medicine, 2001, Jul-19, Volume: 345, Issue:3

    Topics: Adult; Diphosphonates; Female; Histiocytosis, Langerhans-Cell; Humans; Osteolysis; Pain; Pamidronate

2001
Pamidronate in incident pain due to bone metastases.
    Journal of pain and symptom management, 2001, Volume: 22, Issue:2

    Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Diphosphona

2001
Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma.
    Anti-cancer drugs, 2001, Volume: 12, Issue:9

    Topics: Adult; Breast Neoplasms; Diphosphonates; Female; Humans; Lung Neoplasms; Osteoarthropathy, Secondary

2001
More on pamidronate in Langerhans'-cell histiocytosis.
    The New England journal of medicine, 2001, Nov-15, Volume: 345, Issue:20

    Topics: Adolescent; Anti-Inflammatory Agents; Diphosphonates; Histiocytosis, Langerhans-Cell; Humans; Male;

2001
More on pamidronate in Langerhans'-cell histiocytosis.
    The New England journal of medicine, 2001, Nov-15, Volume: 345, Issue:20

    Topics: Anti-Inflammatory Agents; Diphosphonates; Histiocytosis, Langerhans-Cell; Humans; Mevalonic Acid; Os

2001
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.
    Archives of disease in childhood, 2002, Volume: 86, Issue:5

    Topics: Absorptiometry, Photon; Adolescent; Biomarkers; Bone Density; Bone Remodeling; Child; Child, Prescho

2002
Bone scintigraphy following intravenous pamidronate for Paget's disease of bone.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1992, Volume: 33, Issue:9

    Topics: Alkaline Phosphatase; Creatinine; Diphosphonates; Humans; Hydroxyproline; Infusions, Intravenous; Os

1992